# Comparative Characterization of Tumor Microenvironments in Monophasic and Biphasic Synovial Sarcomas

**Authors:** Anna Kosyreva, Enar Jumaniyazova, Alexandra Sentyabreva, Ekaterina Miroshnichenko, Dzhuliia Dzhalilova, Timur Fetisov, Anastasia Tararykova, Anastasiya Lokhonina, Timur Fatkhudinov

PMC · DOI: 10.3390/ijms262010119 · International Journal of Molecular Sciences · 2025-10-17

## TL;DR

This study compares the tumor microenvironments of monophasic and biphasic synovial sarcomas, revealing differences in immune cell infiltration and gene expression.

## Contribution

The study provides a comparative characterization of immune cell infiltration and gene expression in two subtypes of synovial sarcomas.

## Key findings

- Biphasic synovial sarcomas show higher infiltration of CD4+ and CD8+ lymphocytes compared to monophasic tumors.
- Monophasic tumors exhibit higher expression of CDKN2A, EGFR, and PDGFRL genes.
- Monophasic tumors have higher levels of M2 macrophage marker ARG1 compared to biphasic tumors.

## Abstract

The impact of histological subtype on immunogenic properties of the tumor microenvironment in synovial sarcomas (SSs) remains understudied. This study aimed to conduct a comparative assessment of tumor microenvironments in monophasic and biphasic SSs. During the study, biomaterial from nine patients with SS was analyzed using IHC analysis, flow cytometry, and real-time PCR. All tumors were infiltrated with CD45+ leukocytes, including the diffusely scattered CD68+ macrophages. FAP+ cells were identified in 7/9 observations, including both monophasic and biphasic tumors. CD4+ T cells and CD20+ B cells were identified by IHC in biphasic SS. The flow cytometry assay revealed significantly higher counts of CD4+ and CD8+ lymphocytes in biphasic SS. IHC revealed E-cadherin expression specifically in the epithelial component of biphasic SS. Vimentin expression in the mesenchymal component of biphasic SS was stronger than in monophasic tumors. The reverse transcription real-time PCR assay revealed higher expression of tumor markers CDKN2A, EGFR, and PDGFRL in monophasic SS. Expression levels of M2 macrophage marker ARG1 and levels of M1 macrophage marker NOS2 in monophasic SS were higher than in biphasic tumors. Biphasic and monophasic SSs revealed distinct molecular patterns and differential degrees of T lymphocyte and M2 macrophage infiltration. Biphasic SSs are characterized by the presence of lymphocytes in the tumor, while monophasic SSs show more pronounced infiltration with M2 macrophages. Monophasic tumors are characterized by higher expression of cancer-related genes CDKN2A, EGFR, and PDGFRL, which can be considered as potential targets for treatment. Our study is limited to a small sample of patients. This is due to the rarity of synovial sarcoma, as well as the fact that we recruited patients who had not received radiation or chemotherapy before taking the biomaterial. It was these criteria that made it possible to objectively assess the state of the tumor microenvironment.

## Linked entities

- **Genes:** CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029], EGFR (epidermal growth factor receptor) [NCBI Gene 1956], PDGFRL (platelet derived growth factor receptor like) [NCBI Gene 5157], ARG1 (arginase 1) [NCBI Gene 383], NOS2 (nitric oxide synthase 2) [NCBI Gene 4843]
- **Proteins:** shg (shotgun), PRELID1 (PRELI domain containing 1)
- **Diseases:** synovial sarcoma (MONDO:0010434)

## Full-text entities

- **Genes:** CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, FAP (fibroblast activation protein alpha) [NCBI Gene 2191] {aka DPPIV, FAPA, FAPalpha, SIMP}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, PDGFRL (platelet derived growth factor receptor like) [NCBI Gene 5157] {aka PDGRL, PRLTS}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, VIM (vimentin) [NCBI Gene 7431], KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, ARG1 (arginase 1) [NCBI Gene 383]
- **Diseases:** SSs (MESH:D013584), Tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12563643/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12563643/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12563643/full.md

---
Source: https://tomesphere.com/paper/PMC12563643